Golimumab biosimilar is under clinical development by Alvotech and currently in Phase III for Rheumatoid Arthritis. According to GlobalData, Phase III drugs for Rheumatoid Arthritis have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Golimumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Golimumab biosimilar overview
Monoclonal antibody is under development for the treatment of inflammation, rheumatoid arthritis and musculoskeletal diseases. The drug candidate is a biosimilar. It is developed based on SmartFactory GMP manufacturing platform. It is administered through subcutaneous and intravenous route.
Alvotech overview
Alvotech is a biopharmaceutical company that develops, manufactures and commercializes biosimilar medicines. The company’s pipeline immunology products include AVT02, AVT04, AVT05, AVT16 and AVT23 target respiratory diseases; AVT06 and AVT33 for ophthalmology and oncology; AVT03 for bone disease; AVT19, AVT28 and AVT41. Its biosimilars include HUMIRA, STELARA, XOLAIR, PROLIA, SIMPONI, ARIA, EYLEA, ENTYVIO and KEYTRUDA. The company operates in the US, Luxemburg, Switzerland, Canada and Australia, among others. Alvotech is headquartered in Luxemburg.
For a complete picture of Golimumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
